期刊论文详细信息
Memórias do Instituto Oswaldo Cruz
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease
J Antonio Marin-neto2  Anis Rassi Jr1  Alvaro Avezum Jr1  Antonio C Mattos1  Anis Rassi1 
[1] ,Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto Departamento de Medicina InternaRibeirão Preto SP ,Brasil
关键词: Chagas disease;    Chagas cardiomyopathy;    antitrypanosomal therapy;    benznidazole;    clinical trials;   
DOI  :  10.1590/S0074-02762009000900042
来源: SciELO
PDF
【 摘 要 】

Among the pathophysiological derangements operating in the chronic phase of Chagas disease, parasite persistence is likely to constitute the main mechanism of myocardial injury in patients with chronic chagasic cardiomyopathy. The presence of Trypanosoma cruzi in the heart causes a low-grade, but relentless, inflammatory process and induces myocardial autoimmune injury. These facts suggest that trypanocidal therapy may positively impact the clinical course of patients with chronic Chagas heart disease. However, the experimental and clinical evidence currently available is insufficient to support the routine use of etiologic treatment in these patients. The BENEFIT project - Benznidazole Evaluation for Interrupting Trypanosomiasis - is an international, multicenter, double-blind, placebo-controlled trial of trypanocidal treatment with benznidazole in patients with chronic Chagas heart disease. This project is actually comprised of two studies. The pilot study investigates whether etiologic treatment significantly reduces parasite burden, as assessed by polymerase chain reaction-based techniques and also determines the safety and tolerability profile of the trypanocidal drug in this type of chagasic population. The full-scale study determines whether antitrypanosomal therapy with benznidazole reduces mortality and other major cardiovascular clinical outcomes in patients with chronic Chagas heart disease.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License

【 预 览 】
附件列表
Files Size Format View
RO202103040047734ZK.pdf 500KB PDF download
  文献评价指标  
  下载次数:次 浏览次数:次